Reirradiation and Erbitux in the HNSCC

Inclusion Criteria: * Patient with unresectable locoregional recurrence of squamous cell carcinoma in a previously irradiated area (at least 75% of the volume of recidivism must be in an area who have received at least 50 Gy) * The entire tumor volume can be included in a radiation field without the total dose to the spinal cord more than 50 Gy (dose + dose earlier predicted) * Patient with recurrent or second location in the oral cavity, oropharynx, larynx, hypopharynx, cervical lymph nodes or tissues, without distant metastases, * Minimum 12 months after the end of radiotherapy previous * WHO performance status: 0-1, * Evaluable disease by RECIST V.1.1., * Age between 18 and 75 years * The patient may have received prior chemotherapy for relapse for more than five weeks, * The patient may have received cetuximab for the treatment of disease but not for the first relapse, * Hematologic function: ANC ≥ 1500/mm3, Platelets ≥ 100000/mm3, * Normal renal function: serum creatinine ≤ 120 µmol/l and/or creatinine clearance \> 60 ml/min * Normal liver function: bilirubin \<1.5 x ULN, alkaline phosphatase and transaminases \<2.5 x ULN, * Normal cardiac function, assessed clinically. History of cardiovascular disease stabilized for over 12 months * Cons-Lack of medical indications in the proposed treatment, * The dosimetry of previous treatment should be available and the estimated dosimetry must be performed to check the constraints, * All patients of childbearing age should receive effective contraception, * Membership of a social security system (or be a beneficiary of such a plan) under the terms of the Act of August 9, 2004, * Signed informed consent Exclusion Criteria: * Tumors of the nasal cavity and paranasal, * Tumors of other histological type, * Stage IV with distant metastases or multiple tumors, * Time after previous radiotherapy \<12 months, * Less than 75% of the volume of relapse who have previously received at least 50 Gy, * Any medical condition or general-cons would indicate the completion of treatment. Systemic disease or uncontrolled infection, * History of cancer other than head and neck cancer, cutaneous basal cell, carcinoma in situ of the cervix * Any other concurrent anticancer therapy, * Patient receiving another molecule experimental * Pregnant, lactating or without contraception; * Persons deprived of liberty under guardianship * Inability to undergo medical test for geographical, social or psychological * Nasopharyngeal Neoplasms * Patients with active ischemic heart disease or previous myocardial infarction within the last 12 months * Late toxicity dermal or subcutaneous related to previous irradiation of grade\> 2 in the scale CTCAE V.4.